From Seekingalpha · SA Transcripts · · 40s
Helus Pharma Discusses Mental Health Drug Strategy
Helus Pharma reveals Phase 3 plans for new mental health drugs targeting serotonin pathways.
In brief
Helus Pharma reveals Phase 3 plans for new mental health drugs targeting serotonin pathways. Helus Pharma announced Phase 3 clinical trials for novel serotonergic agonists to treat mental health conditions. Originally reported by Seekingalpha.
Helus Pharma
Helus Pharma Inc. published a slide deck discussing clinical pipeline and Phase 3 strategies for novel serotonergic agonists in mental health.
Phase 3 Strategy
The company outlined plans for Phase 3 clinical trials targeting mental health conditions through serotonergic agonists.
Clinical Pipeline
Helus Pharma's clinical pipeline focuses on novel serotonergic agonists for mental health treatment development.
The big picture
Helus Pharma announced Phase 3 clinical trials for novel serotonergic agonists to treat mental health conditions.
